PRECIGEN, INC.

Precigen is a commercial-stage biopharmaceutical company focused on precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases. Utilizing platforms such as AdenoVerse, UltraVector, and UltraCAR-T, the company engineers gene programs and therapies targeting intractable conditions. Its first commercial product is Papzimeos, an adenoviral vector-based immunotherapy approved for treating adult recurrent respiratory papillomatosis. Precigen also maintains an investigational pipeline that includes PRGN-2009 for human papillomavirus-associated malignancies and PRGN-3006 for acute myeloid leukemia. Its offerings serve adult patients, healthcare providers, and integrated delivery networks managing rare diseases and oncology indications.

The company operates internal current good manufacturing practices facilities in Germantown, Maryland, to support drug substance manufacturing and commercial supply. Precigen distributes its approved therapy nationwide across the United States through hospital systems, community clinics, and integrated delivery networks. Additionally, the company seeks international expansion, having submitted a marketing application for European review. Precigen conducts clinical trials at partner institutions across the country and collaborates with entities including the National Cancer Institute.

Summary of the business section of Precigen's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, Exemplar had 20 employees.”